1. 1.Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA: a cancer journal for clinicians. 2021;71(3):264-79. [DOI:10.3322/caac.21657] [PMID] []

2. Garcia Pelaez J, Barbosa Matos R, Gullo I, Carneiro F, Oliveira C. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Molecular oncology. 2021;15(11):2841-67. [DOI:10.1002/1878-0261.12948] [PMID] []

3. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. International journal of molecular sciences. 2020;21(11):4012. [DOI:10.3390/ijms21114012] [PMID] []

4. Grabsch HI, Tan P. Gastric cancer pathology and underlying molecular mechanisms. Digestive surgery. 2013;30(2):150-8. [DOI:10.1159/000350876] [PMID]

5. Díaz P, Valenzuela Valderrama M, Bravo J, Quest AF. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Frontiers in microbiology. 2018;9:5. [DOI:10.3389/fmicb.2018.00005] [PMID] []

6. Bouras E, Tsilidis KK, Triggi M, Siargkas A, Chourdakis M, Haidich A-B. Diet and Risk of Gastric Cancer: An Umbrella Review. Nutrients. 2022;14(9):1764. [DOI:10.3390/nu14091764] [PMID] []

7. Marimuthu A, Jacob HK, Jakharia A, Subbannayya Y, Keerthikumar S, Kashyap MK, et al. Gene expression profiling of gastric cancer. Journal of proteomics & bioinformatics. 2011;4(4):74. [DOI:10.4172/jpb.1000170]

8. Behroozi J, Shahbazi S, Bakhtiarizadeh MR, Mahmoodzadeh H. ADAR expression and copy number variation in patients with advanced gastric cancer. BMC gastroenterology. 2020;20(1):1-9. [DOI:10.1186/s12876-020-01299-8] [PMID] []

9. Behroozi J, Shahbazi S, Bakhtiarizadeh MR, Mahmoodzadeh H. Genome-Wide Characterization of RNA Editing Sites in Primary Gastric Adenocarcinoma through RNA-Seq Data Analysis. International Journal of Genomics. 2020;2020. [DOI:10.21203/rs.3.rs-23058/v1]

10. Tan IB, Ng I, Tai WM, Tan P. Understanding the genetic basis of gastric cancer: recent advances. Expert review of gastroenterology & hepatology. 2012;6(3):335-41. [DOI:10.1586/egh.12.7] [PMID]

11. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS genetics. 2009;5(10):e1000676. [DOI:10.1371/journal.pgen.1000676] [PMID] []

12. Krishnaswamy VR, Korrapati PS. Role of dermatopontin in re-epithelialization: implications on keratinocyte migration and proliferation. Scientific reports. 2014;4(1):1-6. [DOI:10.1038/srep07385] [PMID] []

13. Okamoto O, Fujiwara S. Dermatopontin, a novel player in the biology of the extracellular matrix. Connective tissue research. 2006;47(4):177-89. [DOI:10.1080/03008200600846564] [PMID]

14. Takeda U, Utani A, Wu J, Shinkai H, Adachi E, Koseki H, et al. Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. Journal of investigative dermatology. 2002;119(3):678-83. [DOI:10.1046/j.1523-1747.2002.01863.x] [PMID]

15. Sidgwick G, Bayat A. Extracellular matrix molecules implicated in hypertrophic and keloid scarring. Journal of the European Academy of Dermatology and Venereology. 2012;26(2):141-52. [DOI:10.1111/j.1468-3083.2011.04200.x] [PMID]

16. Yamatoji M, Kasamatsu A, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, et al. Dermatopontin: a potential predictor for metastasis of human oral cancer. International journal of cancer. 2012;130(12):2903-11. [DOI:10.1002/ijc.26328] [PMID]

17. Takeda U, Utani A, Wu J, Adachi E, Koseki H, Taniguchi M, et al. Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. J Invest Dermatol. 2002;119(3):678-83. [DOI:10.1046/j.1523-1747.2002.01863.x] [PMID]

18. Liu S, Qiu J, He G, Geng C, He W, Liu C, et al. Dermatopontin inhibits WNT signaling pathway via CXXC finger protein 4 in hepatocellular carcinoma. Journal of Cancer. 2020;11(21):6288. [DOI:10.7150/jca.47157] [PMID] []

19. Guo Y, Li H, Guan H, Ke W, Liang W, Xiao H, et al. Dermatopontin inhibits papillary thyroid cancer cell proliferation through MYC repression. Molecular and cellular endocrinology. 2019;480:122-32. [DOI:10.1016/j.mce.2018.10.021] [PMID]

20. Cui J, Li F, Wang G, Fang X, Puett JD, Xu Y. Gene-expression signatures can distinguish gastric cancer grades and stages. PloS one. 2011;6(3):e17819. [DOI:10.1371/journal.pone.0017819] [PMID] []

21. Clough E, Barrett T. The gene expression omnibus database. Statistical genomics: Springer; 2016. p. 93-110. [DOI:10.1007/978-1-4939-3578-9_5] [PMID] []

22. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nature methods. 2015;12(4):357. [DOI:10.1038/nmeth.3317] [PMID] []

23. Ebbert MT, Wadsworth ME, Staley LA, Hoyt KL, Pickett B, Miller J, et al. Evaluating the necessity of PCR duplicate removal from next-generation sequencing data and a comparison of approaches. BMC bioinformatics. 2016;17(7):239. [DOI:10.1186/s12859-016-1097-3] [PMID] []

24. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary oncology. 2015;19(1A):A68. [DOI:10.5114/wo.2014.47136] [PMID] []

25. Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322. [DOI:10.18632/oncotarget.10337] [PMID] []

26. Morris LG, Chan TA. Therapeutic targeting of tumor suppressor genes. Cancer. 2015;121(9):1357-68. [DOI:10.1002/cncr.29140] [PMID] []

27. Liu Y, Wu W, Yiyao W, Han S-S, Yuan Y, Huang J, et al. Recent development of gene therapy for pancreatic cancer using the non-viral nanovectors. Biomaterials Science. 2021. [DOI:10.1039/D1BM00748C] [PMID]

28. Liu X, Meng L, Shi Q, Liu S, Cui C, Hu S, et al. Dermatopontin promotes adhesion, spreading and migration of cardiac fibroblasts in vitro. Matrix Biology. 2013;32(1):23-31. [DOI:10.1016/j.matbio.2012.11.014] [PMID]

29. Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, de Boer RA, et al. The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PloS one. 2010;5(9):e12963. [DOI:10.1371/journal.pone.0012963] [PMID] []

30. Li X, Feng P, Ou J, Luo Z, Dai P, Wei D, et al. Dermatopontin is expressed in human liver and is downregulated in hepatocellular carcinoma. Biochemistry (Moscow). 2009;74(9):979-85. [DOI:10.1134/S0006297909090053] [PMID]

31. Huang H, Hao Z, Long L, Yin Z, Wu C, Zhou X, et al. Dermatopontin as a potential pathogenic factor in endometrial cancer. Oncology Letters. 2021;21(5):1-8. https://doi.org/10.3892/ol.2020.12051 https://doi.org/10.3892/ol.2020.12053 https://doi.org/10.3892/ol.2021.12669 [DOI:10.3892/ol.2020.12075] [PMID] []

32. Khan I, Steeg PS. Metastasis suppressors: functional pathways. Laboratory investigation. 2018;98(2):198-210. [DOI:10.1038/labinvest.2017.104] [PMID] []

33. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nature Reviews Cancer. 2011;11(10):726-34. [DOI:10.1038/nrc3130] [PMID] []

34. Fu Y, Feng M-X, Yu J, Ma M-Z, Liu X-J, Li J, et al. DNA methylation-mediated silencing of matricellular protein dermatopontin promotes hepatocellular carcinoma metastasis by α3β1 integrin-Rho GTPase signaling. Oncotarget. 2014;5(16):6701. [DOI:10.18632/oncotarget.2239] [PMID] []